Month: July 2021

SIGNING OF THE AGREEMENTS RELATING TO THE PROPOSED MERGER BETWEEN GROUPE TF1 AND GROUPE M6 Paris, Boulogne-Billancourt, Neuilly-sur-Seine and Luxembourg, 8 July 2021 Following the press release of 17 May 2021 relating to the proposed merger between Groupe TF1 and Groupe M6, the employee representative bodies of Groupe Bouygues, Groupe TF1 and Groupe M6 issued their favourable opinions on the proposed merger on 24 June 2021. Groupe Bouygues and RTL Group thus today announced the signing of agreements relating to the merger between Groupe TF1 and Groupe M6. The completion of the transaction remains subject to the usual condition precedents, in particular the authorizations of the competent authorities1 and the general meetings of Groupe TF1 and Groupe M6. The transaction is aimed to close by the end of 2022.  1 The antitrust authorities...

Kim JohnsonGlobal CEO, Ogilvy HealthNEW YORK, July 08, 2021 (GLOBE NEWSWIRE) — Ogilvy Health today announced that health industry leader Kim Johnson has been appointed Global Chief Executive Officer of Ogilvy Health. Widely respected for her marketing leadership in the health and wellness sector, Kim has worked at the forefront of global health and science innovation on both the agency and client side throughout her career. Kim will oversee all aspects of Ogilvy’s Health business spanning Brand Strategy, Advertising, Public Relations, Experience, Medical Education, HCP Promotion, Market Access, and Patient/Consumer Engagement and be responsible for further accelerating Ogilvy Health’s growth. She will assume the role on July 26. Ogilvy’s Global Chief Executive Officer Andy Main said: “I am thrilled to have someone...

NEXITYSociété anonymeau capital de 280 648 620 eurosSiège Social : 19, rue de Vienne – TSA 5002975801 PARIS Cedex 08444 346 795 RCS Paris Monthly disclosure of the total numberof voting rights and shares composing the share capital in accordance with Articles L. 233-8-II of the French Commercial Code and 223-16 of the General Regulation of the Autorité des Marchés FinanciersInformation cut-off date Total numberof shares Net total number ofvoting rightsJune 30, 2021   56,129,724   Total gross 56,129,724Net total 55,656,675* Net total = Total number of voting rights attached to the shares – shares without voting rights Paris, July 8, 2021AttachmentMonthly disclosure of the total number of voting rights and shares – June 2021 lm

Communiqué de presse – jeudi 08 juillet 2021 – 17h45 ARGAN accompagne la croissance d’ARVATO en lançant l’extension du site de Chanteloup-en-Brie (77) ARGAN, foncière spécialisée dans le développement et la location d’entrepôts PREMIUM, lance la construction d’une nouvelle cellule de 7 000 m² sur son site de Chanteloup-en-Brie exploité par Arvato Services Healthcare France pour le porter à 28 000 m²                                                       Le bâtiment d’origine, composé de 3 cellules, a été développé par ARGAN pour son client ARVATO SERVICES HEALTHCARE France en 2012. Il représente une surface de 21 000 m² dont 2 400 m² de bureaux et locaux sociaux. Edifié sur un terrain de 5,5 hectares, ce site offrait une capacité d’extension aujourd’hui mise en œuvre avec le lancement de la construction d’une quatrième cellule de 7 000...

VINCIT OYJ PÖRSSI-ILMOITUS 8.7.2021                VINCIT OYJ: OMIEN OSAKKEIDEN HANKINTA 8.7.2021         Helsingin Pörssi             Päivämäärä 8.7.2021    Pörssikauppa Osto    Osakelaji VINCIT    Osakemäärä 3,552 osaketta  Keskihinta/ osake 10.3874 EUR  Kokonaishinta 36,896.04 EUR                Yhtiön hallussa olevat omat osakkeet 8.7.2021  tehtyjen kauppojen jälkeen: 259 000 kpl.                  Vincit Oyj:n puolesta             Nordea Pankki Oyj                    Janne Sarvikivi Sami Huttunen           Lisätietoja:      Vincit Oyj, toimitusjohtaja Mikko Kuitunen    p. 040 589 8316                    www.vincit.com             AttachmentVINCIT_8.7_trades

On July 08, 2021 the request of Romus Jarulaitis, a member of the Supervisory Board of AB Žemaitijos Pienas, to be removed from the position of a member of the Supervisory Board was received. The request  will be examined and resolved in accordance with the procedure established by legal acts.LawyerGintaras KeliauskasTel. 868718399  

Efruxifermin (EFX) also improved markers of liver injury, inflammation, lipoproteins, and glycemic control SOUTH SAN FRANCISCO, Calif., July 08, 2021 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that full results of the main portion of its Phase 2a BALANCED trial in biopsy-confirmed NASH patients with F1-F3 fibrosis have been published in Nature Medicine. The manuscript, available at this link, provides a comprehensive analysis showing that pre-cirrhotic NASH patients treated for 16 weeks with Akero’s investigational drug, efruxifermin (EFX), an FGF21 analog, achieved substantial reductions in liver fat, associated with decreases in markers of liver injury and inflammation, and...